« Return to News | Awards & Advancement

Clinical Network Services appoints Francis to BioDesk

Monday, March 4, 2013 02:13 PM

Clinical Network Services (CNS), an Australian-based CRO offering integrated development services in phase I and II trials, has appointed ex-Therapeutic Goods Administration (TGA) toxicologist Dr. Douglas Francis senior regulatory toxicologist for the company’s BioDesk product development planning and regulatory affairs service.

He will provide advice and assistance to international and Australian/New Zealand biotechnology companies in toxicology, pharmacology and drug optimization to support conduct of clinical trials and drug registration in key global markets.

Francis is a U.K./European registered toxicologist and a member of the U.S. Society of Toxicology, the American College of Toxicology, the British Toxicology Society and the Roundtable of Toxicology Consultants.

Most recently, he offered regulatory toxicology services to small and medium pharmaceutical and biotech clients in Australia, Europe and the U.S. through his own consultancy, DF Pre-clinical Services. Previously, he was vice president of drug development for Australian biotech Phylogica, and drug development manager at Pharmaxis.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.